Clinical Significance of Serum IGF-I, IGF-II and IGFBP-3 in Liver Cirrhosis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2004 Aug 17

PMID 15309731

Citations 21

Authors

Yun-Lin Wu

Jing Ye

Shu Zhang

Jie Zhong

Rong-Ping Xi

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the relationship between insulin-like growth factor-I, -II (IGF-I and IGF-II), IGF-binding protein 3 (IGFBP-3) and Child-Pugh score in patients with liver cirrhosis, and to search for potential clinical markers of liver function.

Methods: Forty-four patients with advanced liver cirrhosis of viral origin were divided into 3 groups according to severity of cirrhosis (Child-Pugh score) and 38 healthy subjects served as controls. Serum levels of IGF-I, IGF-II and IGFBP-3 were measured by immunoradiometric assay.

Results: Serum IGF-I, IGF-II and IGFBP-3 levels were significantly lower in patients with cirrhosis than in controls, and serum concentrations of IGF-I, IGF-II and IGFBP-3 were associated with the severity of liver dysfunction, and dropped sharply during the progression of liver failure. Among these 3 parameters, serum IGF-II was the most sensitive and effective indicator for liver dysfunction. Concentrations of IGF-I <30 ng/mL, IGF-II <200 ng/mL and IGFBP-3 <6 ng/mL implied a negative prognosis for patients with liver cirrhosis.

Conclusion: Serum IGF-I, IGF-II and IGFBP-3 may provide a new dimension in the assessment of liver dysfunction. Combined detection of serum IGF-I, IGF-II and IGFBP-3 with Child-Pugh score is more effective in predicting prognosis than Child-Pugh score alone.

Citing Articles

Exposure to PFAS chemicals induces sex-dependent alterations in key rate-limiting steps of lipid metabolism in liver steatosis.

Hari A, AbdulHameed M, Balik-Meisner M, Mav D, Phadke D, Scholl E Front Toxicol. 2024; 6:1390196.

PMID: 38903859 PMC: 11188372. DOI: 10.3389/ftox.2024.1390196.

Insulin-like growth factor 1 predicts decompensation and long-term prognosis in patients with compensated cirrhosis.

Saeki C, Kanai T, Ueda K, Nakano M, Oikawa T, Torisu Y Front Med (Lausanne). 2023; 10:1233928.

PMID: 37554499 PMC: 10405075. DOI: 10.3389/fmed.2023.1233928.

IGF2-NR4A2 Signaling Regulates Macrophage Subtypes to Attenuate Liver Cirrhosis.

Yao L, Hu X, Yuan M, Zhang Q, Liu P, Yang L J Clin Transl Hepatol. 2023; 11(4):787-799.

PMID: 37408817 PMC: 10318280. DOI: 10.14218/JCTH.2022.00392.

Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.

Abu El-Makarem M, Kamel M, Mohamed A, Ali H, Mohamed M, Mohamed A PLoS One. 2022; 17(11):e0277266.

PMID: 36374927 PMC: 9662744. DOI: 10.1371/journal.pone.0277266.

Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B.

Argirion I, Pfeiffer R, Lam T, OBrien T, Yu K, McGlynn K Sci Rep. 2021; 11(1):21194.

PMID: 34782638 PMC: 8593047. DOI: 10.1038/s41598-021-00455-8.

References

Wang X, Chen Z, Zhang L, Chen Y, Li D, Chen F . Expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor and its intervention by interleukin-10 in experimental hepatic fibrosis. World J Gastroenterol. 2003; 9(6):1287-91. PMC: 4611802. DOI: 10.3748/wjg.v9.i6.1287. View

Donaghy A, Delhanty P, Ho K, Williams R, Baxter R . Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol. 2002; 36(6):751-8. DOI: 10.1016/s0168-8278(02)00049-1. View

Inaba T, Saito H, Inoue T, Han I, Furukawa S, Matsuda T . Growth hormone/insulin-like growth factor 1 axis alterations contribute to disturbed protein metabolism in cirrhosis patients after hepatectomy. J Hepatol. 1999; 31(2):271-6. DOI: 10.1016/s0168-8278(99)80224-4. View

Moller S, Juul A, Becker U, Flyvbjerg A, Skakkebaek N, Henriksen J . Concentrations, release, and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I, and growth hormone in different vascular beds in patients with cirrhosis. J Clin Endocrinol Metab. 1995; 80(4):1148-57. DOI: 10.1210/jcem.80.4.7536200. View

Garcia-Fernandez M, Castilla-Cortazar I, Diaz-Sanchez M, Diez Caballero F, Castilla A, Diaz Casares A . Effect of IGF-I on total serum antioxidant status in cirrhotic rats. J Physiol Biochem. 2003; 59(2):145-6. DOI: 10.1007/BF03179879. View

Nedic O, Nikolic J, Prisic S, Acimovic J, Hajdukovic-Dragojlovic L . Reactivity of IGF binding protein-3 isoforms towards concanavalin A in healthy adults and subjects with cirrhosis. Addict Biol. 2003; 8(1):81-8. DOI: 10.1080/1355621031000069927. View

Caregaro L, Alberino F, Amodio P, Merkel C, Angeli P, Plebani M . Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition. 1997; 13(3):185-90. DOI: 10.1016/s0899-9007(96)00399-1. View

Fan Z, Yang D, Cui J, Qin H, Huang C . Expression of insulin like growth factor II and its receptor in hepatocellular carcinogenesis. World J Gastroenterol. 2002; 7(2):285-8. PMC: 4723538. DOI: 10.3748/wjg.v7.i2.285. View

Vyzantiadis T, Theodoridou S, Giouleme O, Harsoulis P, Evgenidis N, Vyzantiadis A . Serum concentrations of insulin-like growth factor-I (IGF-I) in patients with liver cirrhosis. Hepatogastroenterology. 2003; 50(51):814-6. View

10.

Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G . Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a prospective study. Cancer. 2002; 95(12):2539-45. DOI: 10.1002/cncr.11002. View

11.

Ottesen L, Bendtsen F, Flyvbjerg A . The insulin-like growth factor binding protein 3 ternary complex is reduced in cirrhosis. Liver. 2001; 21(5):350-6. DOI: 10.1034/j.1600-0676.2001.210508.x. View

12.

Nikolic J, Todorovic V, Bozic M, Tosic L, Bulajic M, Alempijevic T . Serum insulin-like growth factor (IGF)-II is more closely associated with liver dysfunction than is IGF-I in patients with cirrhosis. Clin Chim Acta. 2000; 294(1-2):169-77. DOI: 10.1016/s0009-8981(99)00254-5. View

13.

Seehofer D, Steinmueller T, Rayes N, Wiegand W, Tullius S, Settmacher U . Pituitary function test and endocrine status in patient with cirrhosis of the liver before and after hepatic transplantation. Ann Transplant. 2002; 7(2):32-7. View

14.

De Palo E, Bassanello M, Lancerin F, Spinella P, Gatti R, DAmico D . GH/IGF system, cirrhosis and liver transplantation. Clin Chim Acta. 2001; 310(1):31-7. DOI: 10.1016/s0009-8981(01)00511-3. View

15.

Petersen K, Jacob R, West A, Sherwin R, Shulman G . Effects of insulin-like growth factor I on glucose metabolism in rats with liver cirrhosis. Am J Physiol. 1998; 273(6):E1189-93. DOI: 10.1152/ajpendo.1997.273.6.E1189. View

16.

Cuneo R, Hickman P, Wallace J, Teh B, Ward G, Veldhuis J . Altered endogenous growth hormone secretory kinetics and diurnal GH-binding protein profiles in adults with chronic liver disease. Clin Endocrinol (Oxf). 1995; 43(3):265-75. DOI: 10.1111/j.1365-2265.1995.tb02031.x. View

17.

Scharf J, Braulke T . The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res. 2004; 35(11-12):685-93. DOI: 10.1055/s-2004-814151. View

18.

Guo X, Chen Y, Jin R . [Experimental and clinical studies of recombinant human growth hormone treatement of hypoproteinemia of liver cirrhosis patients]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2002; 15(4):339-41. View

19.

Muguerza B, Castilla-Cortazar I, Garcia M, Quiroga J, Santidrian S, Prieto J . Antifibrogenic effect in vivo of low doses of insulin-like growth factor-I in cirrhotic rats. Biochim Biophys Acta. 2001; 1536(2-3):185-95. DOI: 10.1016/s0925-4439(01)00045-x. View

20.

Nunez M, Urdaneta E, Santidrian S . Effect of insulin-like growth factor-I on nitrogen balance and intestinal galactose transport in rats with moderate liver cirrhosis. Br J Nutr. 2003; 90(5):929-37. DOI: 10.1079/bjn2003974. View